摘要：Objective: This study aims to determine the mediating effects of psychological empowerment on abusive supervision and turnover intention as perceived by nurses to provide information to change the status of nurse ***: A cross-sectional survey (a questionnaire examining perceptions of abusive supervision,measurement of psychological empowerment,and questionnaire for turnover intention) was used to collect data.A total of 1127 clinical nurses,who were recruited through convenience sampling,participated in the ***: Nurses' average perceived abusive supervision,psychological empowerment,and turnover intention scores were 1.62 ± 0.95,3.24 ± 0.83,and 14.17 ± 3.78,*** empowerment was found to mediate the relationship between abusive supervision and turnover intention (P< 0.01).Turnover intention tends to be stronger and psychological empowerment reduced when nurse managers adopt an abusive leadership ***: Nurses' psychological empowerment is an intermediary variable that predicts the relationship between abusive supervision and turnover *** managers should manage abusive supervision to increase nurses' psychological empowerment and decrease turnover intention.

摘要：Background:Total mesorectum excision(TME)is considered the standard surgical procedure for rectal-cancer *** TME(taTME)is a new procedure to treat low rectal *** published studies have proven that taTME can provide a better-quality resected specimen in low-rectal-cancer patients in comparison to the transabdominal procedure,yet long-term outcomes must be *** designed this non-inferiority trial(TaLaR trial)to compare short-term and long-term outcomes between taTME and laparoscopic TME(lapTME)for rectal ***:The TaLaR trial is a phase III open-labeled multicenter randomized-controlled *** who are diagnosed with rectal cancer with no more than T3N2 stage,and with the tumor location below the peritoneal reflection by magnetic resonance imaging scan,digital rectal examination,or colonoscopy,qualify for this *** calculating,a total of 1,114 patients(557 per group)will be randomly allocated to either the taTME or the lapTME *** endpoints are the 3-year disease-free survival(DFS)rate and the 5-year overall survival(OS)*** endpoints include specimen quality,perioperative results,pelvic and anal function,and quality of ***:The TaLaR trial is expected to clarify whether taTME can achieve comparable oncological outcomes,as well as improve specimen quality and recovery conditions in rectal-cancer patients compared with lapTME.